<p>Acadian Asset Management LLC 在第一季度通过与证券交易委员会的最新 13F 备案显示，将其在 Agenus Inc.（纳斯达克股票代码：AGEN - 免费报告）的持股增加了 1,959.9%。该机构投资者在该时期购入了额外的 720,629 股，持有这家生物技术公司的 757,397 股股票。根据最新的 SEC 备案，Acadian Asset Management LLC 持有的 Agenus 股份价值 439,000 美元，占 Agenus 约 3.73%。</p>
<p>许多其他大型投资者也对该公司的持股进行了调整。Vanguard Group Inc.在第三季度增加了其在 Agenus 的持股比例 1.6%。Vanguard Group Inc.现在拥有 26,938,439 股这家生物技术公司的股票，价值 30,440,000 美元，比上一季度增加了 432,202 股。SG Americas Securities LLC 在第四季度将其在 Agenus 的持股比例增加了 526.6%。SG Americas Securities LLC 现在拥有 198,735 股这家生物技术公司的股票，价值 165,000 美元，比上一季度增加了 167,017 股。Assenagon Asset Management S.A.在第四季度将其在 Agenus 的持股比例增加了 3,008.8%。Assenagon Asset Management S.A.现在拥有 2,306,248 股这家生物技术公司的股票，价值 1,909,000 美元，比上一季度增加了 2,232,064 股。PCG Wealth Advisors LLC 在第四季度将其在 Agenus 的持股比例增加了 65.7%。PCG Wealth Advisors LLC 现在拥有 47,550 股这家生物技术公司的股票，价值 39,000 美元，比上一季度增加了 18,850 股。最后，Cardinal Strategic Wealth Guidance 在第四季度将其在 Agenus 的持股比例增加了 28.2%。Cardinal Strategic Wealth Guidance 现在拥有 910,265 股这家生物技术公司的股票，价值 754,000 美元，比上一季度增加了 200,000 股。机构投资者持有该公司股份的比例为 61.46%。</p>
<h2>分析师评级变动</h2>
<p>许多股票分析师已经发布了关于 AGEN 股票的报告。HC Wainwright 将 Agenus 的评级从 “买入” 调降至 “中性”，并将股票的目标价格从 40.00 美元降至 9.00 美元。StockNews.com 在 4 月 17 日的报告中开始对 Agenus 进行覆盖。他们为该公司设定了 “持有” 评级。Robert W. Baird 将 Agenus 的评级从 “表现优异” 调降至 “中性”，并将公司的价格目标从 35.00 美元降至 8.00 美元。William Blair 将 Agenus 的评级从 “表现优异” 调降至 “市场表现” 评级。最后，Jefferies Financial Group 重申了对 Agenus 的 “持有” 评级，并在 7 月 19 日的报告中将股票的目标价格从 3.00 美元上调至 7.00 美元。六位研究分析师对该股票进行了持有评级，一位给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，共识目标价格为 31.00 美元。</p>
<p><strong>查看我们对 AGEN 的最新股票分析</strong></p>
<h2>Agenus 股价表现</h2>
<p>纳斯达克 AGEN 股票周五开盘价为 6.56 美元。Agenus Inc.的 52 周最低价为 4.78 美元，52 周最高价为 32.00 美元。该股的市值为 1.3775 亿美元，市盈率为-0.51，贝塔系数为 1.32。该公司的 50 日移动平均价为 13.90 美元，200 日移动平均价为 12.52 美元。</p>
<p>Agenus（纳斯达克：AGEN - 获取免费报告）最近发布了其财报，日期为 5 月 7 日。这家生物技术公司在该季度报告中每股亏损 3.04 美元，超过了每股亏损 3.58 美元的分析师预期。该公司在该季度的营收为 2,801 万美元，低于分析师预期的 4,070 万美元。卖方分析师平均预计，Agenus Inc.今年将实现每股盈利-10.73 美元。</p>
<h2>Agenus 简介（免费报告）</h2>
<p>Agenus Inc.是一家临床阶段的生物技术公司，致力于在美国和国际市场发现和开发免疫肿瘤学产品。该公司提供 Retrocyte Display，一种用于识别全人类和人源化单克隆抗体的抗体表达平台；以及展示技术。</p>
<h2>精选文章</h2>
<ul>
<li>我们比 Agenus 更喜欢的五支股票</li>
<li>除了喝咖啡，还有三种投资方式</li>
<li>为什么这两支股票的认购期权交易量会同时激增</li>
<li>什么是认沽期权交易量？</li>
<li>MarketBeat 周评 - 7/22 - 7/26</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>3M 公司的业绩出人意料并加速反弹：现在入市为时尚早</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 625,000% 收益（来自加密交易利润）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODI4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODI4"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Agenus 股票？</h2>
<p>在考虑购买 Agenus 股票之前，您可能需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 Agenus 不在这份名单上。</p>
<p>尽管 Agenus 目前在分析师中的评级为 “持有”，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

安帝君斯

阿卡迪亚

<p>Acadian Asset Management LLC 根据最近向证券交易委员会提交的 13F 文件，在第一季度将其在 Agenus Inc.（纳斯达克股票代码：AGEN）的持仓增加了 1,959.9%。其他大型投资者也对该公司的持仓进行了调整。多家股票分析师发布了关于 Agenus 的报告，一致给出 “持有” 评级，并设定了 31.00 美元的目标股价。Agenus Inc.的市值为 1.3775 亿美元，市盈率为-0.51</p>

<p>Acadian Asset Management LLC lifted its position in Agenus Inc. (NASDAQ:AGEN - Free Report) by 1,959.9% in the first quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 757,397 shares of the biotechnology company's stock after buying an additional 720,629 shares during the period. Acadian Asset Management LLC owned about 3.73% of Agenus worth $439,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Acadian Asset Management LLC 在第一季度通过与证券交易委员会的最新 13F 备案显示，将其在 Agenus Inc.（纳斯达克股票代码：AGEN - 免费报告）的持股增加了 1,959.9%。该机构投资者在该时期购入了额外的 720,629 股，持有这家生物技术公司的 757,397 股股票。根据最新的 SEC 备案，Acadian Asset Management LLC 持有的 Agenus 股份价值 439,000 美元，占 Agenus 约 3.73%。</p>
</div><p>A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Agenus by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 26,938,439 shares of the biotechnology company's stock worth $30,440,000 after purchasing an additional 432,202 shares in the last quarter. SG Americas Securities LLC increased its holdings in Agenus by 526.6% during the 4th quarter. SG Americas Securities LLC now owns 198,735 shares of the biotechnology company's stock worth $165,000 after purchasing an additional 167,017 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Agenus by 3,008.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company's stock worth $1,909,000 after purchasing an additional 2,232,064 shares in the last quarter. PCG Wealth Advisors LLC increased its holdings in Agenus by 65.7% during the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 18,850 shares in the last quarter. Finally, Cardinal Strategic Wealth Guidance increased its holdings in Agenus by 28.2% during the 4th quarter. Cardinal Strategic Wealth Guidance now owns 910,265 shares of the biotechnology company's stock worth $754,000 after purchasing an additional 200,000 shares in the last quarter. Institutional investors own 61.46% of the company's stock.</p>
<div class="lb-trans"><p>许多其他大型投资者也对该公司的持股进行了调整。Vanguard Group Inc.在第三季度增加了其在 Agenus 的持股比例 1.6%。Vanguard Group Inc.现在拥有 26,938,439 股这家生物技术公司的股票，价值 30,440,000 美元，比上一季度增加了 432,202 股。SG Americas Securities LLC 在第四季度将其在 Agenus 的持股比例增加了 526.6%。SG Americas Securities LLC 现在拥有 198,735 股这家生物技术公司的股票，价值 165,000 美元，比上一季度增加了 167,017 股。Assenagon Asset Management S.A.在第四季度将其在 Agenus 的持股比例增加了 3,008.8%。Assenagon Asset Management S.A.现在拥有 2,306,248 股这家生物技术公司的股票，价值 1,909,000 美元，比上一季度增加了 2,232,064 股。PCG Wealth Advisors LLC 在第四季度将其在 Agenus 的持股比例增加了 65.7%。PCG Wealth Advisors LLC 现在拥有 47,550 股这家生物技术公司的股票，价值 39,000 美元，比上一季度增加了 18,850 股。最后，Cardinal Strategic Wealth Guidance 在第四季度将其在 Agenus 的持股比例增加了 28.2%。Cardinal Strategic Wealth Guidance 现在拥有 910,265 股这家生物技术公司的股票，价值 754,000 美元，比上一季度增加了 200,000 股。机构投资者持有该公司股份的比例为 61.46%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of equities analysts have issued reports on AGEN shares. HC Wainwright cut Agenus from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and lowered their target price for the stock from $40.00 to $9.00 in a report on Thursday, July 18th. StockNews.com started coverage on Agenus in a report on Wednesday, April 17th. They set a &#34;hold&#34; rating for the company. Robert W. Baird cut Agenus from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and decreased their price objective for the company from $35.00 to $8.00 in a report on Friday, July 19th. William Blair cut Agenus from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Thursday, July 18th. Finally, Jefferies Financial Group restated a &#34;hold&#34; rating and issued a $7.00 price objective (up previously from $3.00) on shares of Agenus in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and a consensus price target of $31.00.</p>
<div class="lb-trans"><p>许多股票分析师已经发布了关于 AGEN 股票的报告。HC Wainwright 将 Agenus 的评级从 “买入” 调降至 “中性”，并将股票的目标价格从 40.00 美元降至 9.00 美元。StockNews.com 在 4 月 17 日的报告中开始对 Agenus 进行覆盖。他们为该公司设定了 “持有” 评级。Robert W. Baird 将 Agenus 的评级从 “表现优异” 调降至 “中性”，并将公司的价格目标从 35.00 美元降至 8.00 美元。William Blair 将 Agenus 的评级从 “表现优异” 调降至 “市场表现” 评级。最后，Jefferies Financial Group 重申了对 Agenus 的 “持有” 评级，并在 7 月 19 日的报告中将股票的目标价格从 3.00 美元上调至 7.00 美元。六位研究分析师对该股票进行了持有评级，一位给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，共识目标价格为 31.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on AGEN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AGEN 的最新股票分析</strong></p>
</div><h2>Agenus Price Performance</h2>
<div class="lb-trans"><h2>Agenus 股价表现</h2>
</div><p>Shares of NASDAQ AGEN opened at $6.56 on Friday. Agenus Inc. has a fifty-two week low of $4.78 and a fifty-two week high of $32.00. The stock has a market capitalization of $137.75 million, a price-to-earnings ratio of -0.51 and a beta of 1.32. The business has a 50-day moving average of $13.90 and a 200-day moving average of $12.52.</p>
<div class="lb-trans"><p>纳斯达克 AGEN 股票周五开盘价为 6.56 美元。Agenus Inc.的 52 周最低价为 4.78 美元，52 周最高价为 32.00 美元。该股的市值为 1.3775 亿美元，市盈率为-0.51，贝塔系数为 1.32。该公司的 50 日移动平均价为 13.90 美元，200 日移动平均价为 12.52 美元。</p>
</div><p>Agenus (NASDAQ:AGEN - Get Free Report) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.58) by $0.54. The firm had revenue of $28.01 million during the quarter, compared to analyst estimates of $40.70 million. On average, sell-side analysts expect that Agenus Inc. will post -10.73 EPS for the current year.</p>
<div class="lb-trans"><p>Agenus（纳斯达克：AGEN - 获取免费报告）最近发布了其财报，日期为 5 月 7 日。这家生物技术公司在该季度报告中每股亏损 3.04 美元，超过了每股亏损 3.58 美元的分析师预期。该公司在该季度的营收为 2,801 万美元，低于分析师预期的 4,070 万美元。卖方分析师平均预计，Agenus Inc.今年将实现每股盈利-10.73 美元。</p>
</div><h2>Agenus Profile (Free Report)</h2>
<div class="lb-trans"><h2>Agenus 简介（免费报告）</h2>
</div><p>Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.</p>
<div class="lb-trans"><p>Agenus Inc.是一家临床阶段的生物技术公司，致力于在美国和国际市场发现和开发免疫肿瘤学产品。该公司提供 Retrocyte Display，一种用于识别全人类和人源化单克隆抗体的抗体表达平台；以及展示技术。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Agenus</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Why Call Options Volume for These 2 Stocks Spiked Together</li>
<li>What is Put Option Volume?</li>
<li>MarketBeat Week in Review – 7/22 - 7/26</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们比 Agenus 更喜欢的五支股票</li>
<li>除了喝咖啡，还有三种投资方式</li>
<li>为什么这两支股票的认购期权交易量会同时激增</li>
<li>什么是认沽期权交易量？</li>
<li>MarketBeat 周评 - 7/22 - 7/26</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>3M 公司的业绩出人意料并加速反弹：现在入市为时尚早</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AGEN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ 625,000% Gain (From Crypto Swap Profits)(Ad)</p>
<div class="lb-trans"><p>→ 625,000% 收益（来自加密交易利润）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODI4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8828&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Agenus right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Agenus 股票？</h2>
</div><p>Before you consider Agenus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Agenus 股票之前，您可能需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 Agenus 不在这份名单上。</p>
</div><p>While Agenus currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Agenus 目前在分析师中的评级为 “持有”，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

阿卡迪亚资产管理公司购买了 720,629 股安帝君斯公司（NASDAQ:AGEN）的股票